Vascular factors and prevention of dementia

References

• Age-Related Eye Disease Study Research Group. Impact of antioxidants, zinc, and copper on cognition in the elderly. A randomized, controlled trial. Neurology 2004; 63: 1705–1707
   Google Scholar
• Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of Rofecoxib or Naproxen vs. Placebo on Alzheimer Disease 2003
   Google Scholar
• Aleman A, Muller M, De Haan EH, Van Der Schouw YT. Vascular risk factors and cognitive function in a sample of independently living men. Neurobiology of Aging 2005; 26: 485–90
   PubMed Web of Science ®Google Scholar
• Allen KV, Frier BM, Strachan MWJ. The relationship between type 2 diabetes and cognitive dysfunction: Longitudinal studies and their methodological limitations. European Journal of Pharmacology 2004; 490: 169–175
   PubMed Web of Science ®Google Scholar
• Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: A meta-analysis of prospective studies. American Journal of Epidemiology 2007; 166: 367–378
   PubMed Web of Science ®Google Scholar
• Areosa Sastre A, Grimley Evans J. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2002; 4, Art. No. CD003804. DOI: 10.1002/14651858.CD003804
   Google Scholar
• Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Archives of Neurology 2004; 61: 661–666
   PubMed Web of Science ®Google Scholar
• Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database of Systematic Reviews 2006; 3, Art. No. CD006104. DOI: 10.1002/14651858.CD006104
   Google Scholar
• Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2007; 1, Art. No. CD003120. DOI: 10.1002/14651858.CD003120.pub2
   Google Scholar
• Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2005; 3, Art. No. CD001190. DOI: 10.1002/14651858.CD001190.pub2
   Google Scholar
• Blacker D. Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer's disease in the long term. Evidence Based Mental Health 2006; 9: 20
   Google Scholar
• Borenstein AR, Wu Y, Mortimer JA, Schellenberg GD, Mccormick WC, Bowen JD, et al. Developmental and vascular risk factors for Alzheimer's disease. Neurobiology of Aging 2005; 26: 325–334
   PubMed Web of Science ®Google Scholar
• Brayne C. The elephant in the room-healthy brains in later life, epidemiology and public health. National Review of Neuroscience 2007; 8: 233–239
   PubMed Web of Science ®Google Scholar
• Brayne C, Gao L, Dewey M, Matthews FE. Dementia before death in ageing societies–The promise of prevention and the reality. PLoS Medicine 2006; 3: 1922–1930
   Web of Science ®Google Scholar
• Brayne C, Gao L, Dewey M, Matthews FE. Investigators Medical Research Council Cognitive Function and Ageing Study Dementia before Death in Ageing Societies–The Promise of Prevention and the Reality. PLoS Medicine 2006; 3(10)e397, DOI:10.1371/journal.pmed.0030397
   PubMed Web of Science ®Google Scholar
• Brayne C, Gill C, Huppert FA, Barkley C, Gehlhaar E, Girling DM, et al. Incidence of clinically diagnosed subtypes of dementia in an elderly population. Cambridge Project for Later Life. British Journal of Psychiatry 1995; 167: 255–262
   PubMed Web of Science ®Google Scholar
• Breteler MM, Bots ML, Ott A, Hofman A. Risk factors for vascular disease and dementia. Haemostasis 1998; 28: 167–173
   PubMedGoogle Scholar
• Breteler MMB. Vascular involvement in cognitive decline and dementia: Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Annals of the New York Academy of Science 2000; 903: 457–465
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia 2007; 3: 186–191
   PubMed Web of Science ®Google Scholar
• Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics 2004; 16: 129–140
   PubMed Web of Science ®Google Scholar
• Coelho Filho JM, Birks J. Physostigmine for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2001; 2, Art. No. CD001499. DOI: 10.1002/14651858.CD001499
   Google Scholar
• Dartigues JF, Letenneur L, Joly P, Helmer C, Orgogozo J, Commenges D. Age specific risk of dementia according to gender, education and wine consumption. Neurobiology of Aging 2000; 21: 64
   Google Scholar
• De Craen AJM, Gussekloo J, Vrijsen B, Westendorp RGJ. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. American Journal of Epidemiology 2005; 161: 114–120
   PubMed Web of Science ®Google Scholar
• De La Torre JC. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 2002; 33: 1152–1162
   PubMed Web of Science ®Google Scholar
• Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?. Journal of the Neurological Sciences 2005; 229–230: 151–155
   PubMed Web of Science ®Google Scholar
• Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. Journal of the Neurological Sciences 2004; 226: 13–17
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366: 2112–2117
   PubMed Web of Science ®Google Scholar
• Fontbonne A, Berr C, Ducimetiere P, Alperovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: Results of the Epidemiology of Vascular Aging Study. Diabetes Care 2001; 24: 366–370
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351
   PubMed Web of Science ®Google Scholar
• Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurology 2004; 3: 343–353
   PubMed Web of Science ®Google Scholar
• Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: Review of the epidemiological studies. Behavioural Brain Research 2000; 113: 117–120
   PubMed Web of Science ®Google Scholar
• Fratiglioni L, Winblad B, Von Strauss E. Prevention of Alzheimer's disease and dementia. Major findings from the Kungsholmen Project. Physiology & Behavior 2007; 92: 98–104
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Crane PK, Breitner JC, Mccormick W, Bowen JD, et al. Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. Journal of the American Geriatrics Society 2007; 56: 291–295
   Google Scholar
• Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE E4 in modulating effects of other risk factors for cognitive decline in elderly persons. Journal of the American Mathematical Association 1999; 282: 40–46
   PubMed Web of Science ®Google Scholar
• Hervé Allain DB-FYA. Treatment of the mild cognitive impairment (MCI). Human Psychopharmacology: Clinical and Experimental 2007; 22: 189–197
   Google Scholar
• Hudson S, Tabet N. Acetyl-l-carnitine for dementia. Cochrane Database of Systematic Reviews 2003; 2, Art. No. CD003158. DOI: 10.1002/14651858.CD003158
   Google Scholar
• Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: Lessons for the future. Journal of Neurol Neurosurg Psychiatry 2005; 77: 429–438
   Google Scholar
• Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627–1631
   PubMed Web of Science ®Google Scholar
• Jones R, Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2002; 2, Art. No. CD003153. DOI: 10.1002/14651858.CD003153
   Google Scholar
• Jorm AF, Jolley D. The incidence of dementia: A meta-analysis. Neurology 1998; 51: 728–733
   PubMed Web of Science ®Google Scholar
• Kalaria RN. Comparison between Alzheimer's disease and vascular disease: Implications for treatment. Neurological Research 2003; 25: 661–664
   PubMed Web of Science ®Google Scholar
• Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular disease: A meta-analysis of randomised controlled trials. Lancet Neurology 2007; 6: 782–792
   PubMed Web of Science ®Google Scholar
• Kawas C, Resnick. S, Morrison A, Brookmeyer R. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease. Neurology 1997; 48: 1517–1521
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. British Medical Journal 2001; 322: 1447–1451
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Nissinen A, Soininen H, Tuomilehto J. Vascular risk factors, ApoE epsilon 4 allele, and gender and the risk of Alzheimer's disease: Perspectives on prevention. Drug Development Research 2002; 56: 85–94
   Google Scholar
• Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study. Lancet Neurology 2006; 5: 735–741
   PubMed Web of Science ®Google Scholar
• Launer LJ. The epidemiologic study of dementia: A life-long quest?. Neurobiological Aging 2005; 26: 335–40
   Google Scholar
• Laurin D, Verreault R, Lindsay J, Macpherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Archives of Neurology 2001; 58: 498–504
   PubMed Web of Science ®Google Scholar
• Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, et al. Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology 2004; 63: 1624–1628
   PubMed Web of Science ®Google Scholar
• Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annual Review of Medicine 2006; 57: 513–533
   PubMed Web of Science ®Google Scholar
• Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group Neurology 2000; 54: S4–S9
   PubMed Web of Science ®Google Scholar
• López-Arrieta JLA, Sanz FJ. Nicotine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2001; 2, Art. No. CD001749. DOI: 10.1002/14651858.CD001749
   Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2005; 4, Art. No. CD001747. DOI: 10.1002/14651858.CD001747.pub3
   Google Scholar
• Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545–551
   PubMed Web of Science ®Google Scholar
• Massoud F, Belleville S, Bergman H, Kirk J, Chertkow H, Nasreddine Z, et al. Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy. Alzheimer's & Dementia 2007; 3: 283–291
   PubMed Web of Science ®Google Scholar
• Matthews FE, Stephan BCM, Bond J, Mckeith I, Brayne C. Operationalisation of mild cognitive impairment: A graphical approach. PLoS Med 2007; 4: e304, DOI: 31031371/journal.pmed.0040304, MRC CFAS.
   Google Scholar
• Matthews FE, Stephan BCM, McKeith I, Bond J, Brayne C. MRC CFAS. Two-Year progression from mild cognitive impairment to dementia: To what extent do different definitions agree?. Journal of the American Geriatrics Society, (In Press).
   Google Scholar
• McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2006; 2, Art. No. CD004034. DOI: 10.1002/14651858.CD004034.pub2
   Google Scholar
• McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2003
   Google Scholar
• Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. British Medical Journal 1985; 291: 97–104
   PubMed Web of Science ®Google Scholar
• Meyer JS, Xu GL, Thornby J, Chowdhury M, Quach M. Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging. Journal of the Neurological Sciences 2002; 201: 19–25
   PubMed Web of Science ®Google Scholar
• Mielke MM, Zandi PP. Hematologic risk factors of vascular disease and their relation to dementia. Dementia and Geriatric Cognitive Disorders 2006; 21: 335–352
   Google Scholar
• O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurology 2003; 2: 89–98
   PubMed Web of Science ®Google Scholar
• Patterson C, Feightner J, Garcia A, Macknight C. General risk factors for dementia: A systematic evidence review. Alzheimer's & Dementia 2007; 3: 341–347
   PubMed Web of Science ®Google Scholar
• Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Annals of Pharmacotherapy 2004; 38: 1389–1394
   PubMed Web of Science ®Google Scholar
• Purandare N, Ballard C, Burns A. Preventing dementia. Advances in Psychiatric Treatment 2005; 11: 176–183
   Google Scholar
• Rands G, Orrel M, Spector A. Aspirin for vascular disease. Cochrane Database of Systematic Reviews 2000; 3, Art. No. CD001296. DOI: 10.1002/14651858.CD001296
   Google Scholar
• Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Conversion of mild cognitive impairment to dementia: Predictive role of mild cognitive impairment subtypes and vascular risk factors. Dementia and Geriatric Cognitive Disorders 2006; 21: 51–58
   PubMed Web of Science ®Google Scholar
• Roberson ED, Mucke L. 100 years and counting: Prospects for defeating Alzheimer's disease. Science 2006; 314: 781–784
   PubMed Web of Science ®Google Scholar
• Román SC. Vascular disease prevention: A risk factor analysis. Cerebrovascular Diseases 2005; 20: 91–100
   PubMedGoogle Scholar
• Sastre A, Grimley EJ. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2002; 4
   Google Scholar
• Sauer J, Tabet N, Howard RA. Alpha lipoic acid for dementia. Cochrane Database of Systematic Reviews 2004; 1, Art. No. CD004244. DOI: 10.1002/14651858.CD004244.pub2
   Google Scholar
• Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Archives of Neurology 2006; 63: 1709–1717
   PubMed Web of Science ®Google Scholar
• Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database of Systematic Reviews 2001; 3, Art. No. CD003160. DOI: 10.1002/14651858.CD003160
   Google Scholar
• Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. Journal of the American Medical Association 2003; 289: 2651–2662
   PubMed Web of Science ®Google Scholar
• Siuda J, Gorzkowska A, Opala G, Ochudlo S. Vascular risk factors and intensity of cognitive dysfunction in MCI. Journal of the Neurological Sciences 2007; 257: 202–205
   Google Scholar
• Skoog B, Lernfelt S, Landahl B, Palmertz L-A, Andreasson L, Nilsson G, et al. 5-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–1145
   PubMed Web of Science ®Google Scholar
• Small BJ, Rosnick CB, Fratiglioni L, Backman L. Apolipoprotein E and cognitive performance: A meta-analysis. Psychology of Aging 2004; 19: 592–600
   PubMed Web of Science ®Google Scholar
• Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. Journal of the American Medical Association 1997; 277: 813–817
   PubMed Web of Science ®Google Scholar
• Solfrizzi V, Panza F, Colacicco AM, D'introno A, Capurso C, Torres F, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 1882–1891
   PubMed Web of Science ®Google Scholar
• Stephan BCM, Matthews FE, Mckeith I, Bond J, Brayne C, MRC CFAS. Early cognitive change in the general population: How do different definitions work?. Journal of the American Geriatrics Society 2007; 55: 1534–1540
   Google Scholar
• Tervo S, Kivipelto M, Hanninen T, Vanhanen M, Hallikainen M, Mannermaa A, et al. Incidence and risk factors for mild cognitive impairment: A population-based three-year follow-up study of cognitively healthy elderly subjects. Dementia and Geriatric Cognitive Disorders 2004; 17: 196–203
   PubMed Web of Science ®Google Scholar
• Three-City Study Group. Vascular factors and risk of dementia: Design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology 2003; 22: 316–325
   Google Scholar
• Wilson RS, Beck TL, Bienias JL, Bennett DA. Terminal cognitive decline: Accelerated Loss of Cognition in the Last Years of Life. Psychosomatic Medicine 2007; 69: 131–137
   PubMed Web of Science ®Google Scholar
• Wilson RS, Bennett DA, Bienias JL, Aggarwal NT, Mendes De Leon CF, Morris MC, et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology 2002; 59: 1910–1914
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer's & Dementia 2007; 3: 81–91
   PubMed Web of Science ®Google Scholar
• Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology 2000; 57: 1439–1443
   PubMed Web of Science ®Google Scholar
• Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63: 658–663
   PubMed Web of Science ®Google Scholar
• Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Archives of General Psychiatry 2005; 62: 217–224
   PubMed Web of Science ®Google Scholar
• Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: A meta-analysis. Dementia and Geriatric Cognitive Disorders 2007; 23: 194–201
   Web of Science ®Google Scholar